Description of the active substance:
This information is a reference and it is not enough that the drug has been prescribed by a doctor ..
PHARMACHOLOGIC EFFECT
The blocker of histamine H 2 receptors of the third generation. Suppresses the production of hydrochloric acid, both basal and stimulated with histamine, gastrin and, to a lesser extent, acetylcholine. Simultaneously with a decrease in the production of hydrochloric acid and an increase in pH, the activity of pepsin decreases. The duration of action with a single dose depends on the dose and is from 12 to 24 hours.
PHARMACOKINETICS
After ingestion quickly, but not completely, absorbed from the digestive tract. C max in blood plasma is achieved after 2 hours. Bioavailability is 40-45% and slightly changes in the presence of food.
T 1/2 from the plasma is about 3 hours and increases in patients with impaired renal function. Binding with proteins is 15-20%. A small portion of the active substance is metabolized in the liver to form famotidine S-oxide. The most part is excreted unchanged in the urine.
INDICATIONS
Treatment and prevention of relapses of peptic ulcer of stomach and duodenum, reflux esophagitis, Zollinger-Ellison syndrome, diseases and conditions accompanied by increased secretion of gastric juice, prevention of erosive and ulcerative gastrointestinal lesions on the background of NSAID administration; bleeding from the upper gastrointestinal tract (for intravenous administration, as part of complex treatment).
DOSING MODE
Individual, depending on the indications.
Inside with the purpose of treatment apply 10-20 mg 2 times / day or 40 mg 1 time / day. If necessary, the daily dose can be increased to 80-160 mg. For the purpose of prevention - 20 mg 1 time / day before bedtime.
With iv introduction, a single dose is 20 mg, the interval between administrations is 12 hours.
At CC less than 30 ml / min or with a serum creatinine concentration of more than 3 mg / dl, the dose should be reduced to 20 mg / day.
SIDE EFFECT
From the digestive system: may lack of appetite, dry mouth, flavors, nausea, vomiting, bloating, diarrhea, or constipation; in some cases - the development of cholestatic jaundice, an increase in the level of transaminases in the blood plasma.
From the side of the central nervous system: there may be a headache, fatigue, tinnitus, transient mental disorders.
From the cardiovascular system: rarely - arrhythmia.
From the hemopoietic system: very rarely - agranulocytosis, pancytopenia, leukopenia, thrombocytopenia.
From the musculoskeletal system: there may be muscle pains, joint pain.
Allergic reactions: skin pruritus, bronchospasm, fever are possible.
Dermatological reactions: alopecia, common acne, dry skin are possible.
Local reactions: irritation at the injection site.
CONTRAINDICATIONS
Pregnancy, lactation, hypersensitivity to famotidine.
PREGNANCY AND LACTATION
Contraindicated in pregnancy and lactation.
Famotidine is excreted in breast milk.
APPLICATION FOR FUNCTIONS OF THE LIVER
Use with caution in patients with impaired renal function.
APPLICATION FOR VIOLATIONS OF THE FUNCTION OF KIDNEYS
Use with caution in patients with impaired hepatic function.
APPLICATION FOR CHILDREN
The clinical experience of famotidine in children is limited.
SPECIAL INSTRUCTIONS
Use with caution in patients with impaired renal and hepatic function.
Before starting treatment, it is necessary to exclude the possibility of having a malignant disease of the esophagus, stomach or duodenum.
Does not change the activity of microsomal enzymes of the liver.
It should be observed the interval between taking antacids and famotidine for at least 1-2 hours.
The clinical experience of famotidine in children is limited.
DRUG INTERACTION
With simultaneous use with anticoagulants, the possibility of increasing prothrombin time and development of bleeding is not ruled out.
With simultaneous use with antacids, magnesium hydroxide and aluminum hydroxide, a decrease in the absorption of famotidine is possible.
With simultaneous application with itraconazole, it is possible to reduce the concentration of itraconazole in the blood plasma and reduce its effectiveness.
With simultaneous use with nifedipine, the case of a decrease in the minute volume of the heart and cardiac output is described, apparently due to the enhancement of the negative inotropic effect of nifedipine.
With simultaneous use with norfloxacin, the concentration of norfloxacin in the blood plasma decreases; with probenecid - the concentration of famotidine in the blood plasma increases.
With simultaneous application, the case of increasing the concentration of phenytoin in plasma with a risk of developing toxic effects has been described.
With simultaneous use, the bioavailability of cefpodoxime decreases, apparently due to a decrease in its solubility in the contents of the stomach when the pH of the gastric juice is increased under the influence of famotidine.
With simultaneous application with cyclosporine, a slight increase in the concentration of cyclosporine in the blood plasma is possible.
